Profile | GDS2987 / GI_10863982-S |
Title | Comparison of Rho kinase inhibitor and atorvastatin effects on primary cell lines |
Organism | Homo sapiens |
Sample | Title | Value | Rank |
---|---|---|---|
GSM214810 | HMVEC_vehicle_rep1 | 12.4 | 41 |
GSM215244 | HMVEC_vehicle_rep2 | 21.2 | 47 |
GSM215253 | HMVEC_vehicle_rep3 | ||
GSM215254 | HMVEC_atorvastatin_rep1 | 39.6 | 65 |
GSM215282 | HMVEC_atorvastatin_rep3 | ||
GSM215344 | HMVEC_atorvastatin_rep2 | ||
GSM215283 | HMVEC_atorvastatin_mevalonate_rep1 | 32.8 | 53 |
GSM215284 | HMVEC_atorvastatin_mevalonate_rep2 | 2.6 | 6 |
GSM215293 | HMVEC_atorvastatin_mevalonate_rep3 | 7.7 | 13 |
GSM215294 | HMVEC_SLx2119_rep1 | 6.6 | 24 |
GSM215295 | HMVEC_SLx2119_rep2 | 4.9 | 10 |
GSM215296 | HMVEC_SLx2119_rep3 | 1.2 | 2 |
GSM215297 | PASMC_vehicle_rep1 | 27.2 | 39 |
GSM215298 | PASMC_vehicle_rep2 | ||
GSM215310 | PASMC_vehicle_rep3 | 15.4 | 25 |
GSM215311 | PASMC_atorvastatin_rep1 | 28.8 | 45 |
GSM215312 | PASMC_atorvastatin_rep2 | 59.1 | 64 |
GSM215313 | PASMC_atorvastatin_rep3 | ||
GSM215324 | PASMC_atorvastatin_mevalonate_rep1 | 8.6 | 15 |
GSM215325 | PASMC_atorvastatin_mevalonate_rep2 | 17.2 | 32 |
GSM215326 | PASMC_atorvastatin_mevalonate_rep3 | 7.5 | 13 |
GSM215327 | PASMC_SLx2119_rep1 | ||
GSM215328 | PASMC_SLx2119_rep2 | 30.9 | 49 |
GSM215329 | PASMC_SLx2119_rep3 | ||
GSM215330 | Fibroblasts_vehicle_rep1 | 23.2 | 47 |
GSM215331 | Fibroblasts_vehicle_rep2 | 3.2 | 9 |
GSM215332 | Fibroblasts_vehicle_rep3 | 10.6 | 34 |
GSM215333 | Fibroblasts_atorvastatin_rep1 | 6.5 | 18 |
GSM215334 | Fibroblasts_atorvastatin_rep2 | 9.3 | 26 |
GSM215335 | Fibroblasts_atorvastatin_rep3 | ||
GSM215336 | Fibroblasts_atorvastatin_mevalonate_rep1 | 22.2 | 56 |
GSM215337 | Fibroblasts_atorvastatin_mevalonate_rep2 | 3.8 | 12 |
GSM215338 | Fibroblasts_atorvastatin_mevalonate_rep3 | 1.2 | 4 |
GSM215339 | Fibroblasts_SLx2119_rep1 | ||
GSM215340 | Fibroblasts_SLx2119_rep2 | 8 | 22 |
GSM215341 | Fibroblasts_SLx2119_rep3 |